文献速递糖尿病肥胖与代谢综合征

肠系膜内脏脂肪切除术改善2型糖尿病患者糖耐量:一项先导研究

Mesenteric Visceral Lipectomy Improves Glucose Tolerance in Patients With Type 2 Diabetes: A Pilot Study.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本先导研究采用靶向细胞分离与提取技术(TC-SET)切除7例肥胖且血糖控制不佳的2型糖尿病(T2D)患者的小肠系膜脂肪,观察其对血糖控制和胰岛素敏感性的影响。术后第6个月,糖化血红蛋白(HbA1c)和空腹血糖(FPG)均显著下降,葡萄糖目标范围内时间(TIR)从22%升至74%;第12个月部分指标有所回升,但肝脏脂肪含量显著下降,胰岛素分泌和处置指数改善持续存在。作者认为肠系膜内脏脂肪切除术(MVL)有潜力成为改善T2D血糖控制的新型微创方法,但需进一步对照研究证实。

要点

  • 7例肥胖且控制不佳的T2D患者接受小肠系膜脂肪切除,第6个月HbA1c降至7.7%(P = .01)、FPG降至140 mg/dL(P < .01)。
  • TIR从22%升至第6个月74%(P < .001),第12个月为50%(P < .05);内源性葡萄糖产生抑制率从29%升至第6个月45%(P < .05)。
  • 第12个月FPG(172 mg/dL,P = .02)和HbA1c(8.1%,P = .10)呈上升趋势,体重和体脂百分比轻度下降(P < .05)。

核心结论

  • 肠系膜内脏脂肪切除术(MVL)显示出作为改善控制不佳T2D患者血糖控制的新型微创方法的潜力,但需要进一步对照研究来证实这些发现并更好地理解MVL的潜在获益。

研究设计与样本

  • 先导研究,采用靶向细胞分离与提取技术(TC-SET)切除小肠系膜脂肪,纳入7例肥胖且血糖控制不佳的T2D患者(HbA1c = 8.9% ± 0.2%;FPG = 211 ± 12 mg/dL)。

主要发现

  • 第6个月HbA1c显著降至7.7%(P = .01),FPG显著降至140 mg/dL(P < .01)。
  • 第12个月FPG为172 mg/dL(P = .02)、HbA1c为8.1%(P = .10),两者均呈上升趋势。
  • TIR从22%升至第6个月74%(P < .001)和第12个月50%(P < .05)。
  • 内源性(肝脏)葡萄糖产生抑制率从29%升至第6个月45%(P < .05)和第12个月43%(P < .01);全身(肌肉)胰岛素介导的葡萄糖处置在第6个月和第12个月均无显著变化。
  • 第12个月体重(106.8降至103.3 kg)和体脂百分比(33.3降至31.6%)均轻度下降(P < .05),肝脏脂肪含量(氢-1磁共振波谱)显著下降(23.9 ± 3.7%降至19.1 ± 3.4%,P < .005);口服葡萄糖耐量试验中胰岛素分泌和处置指数第6个月增加超过2倍(均P < .05),且改善持续至12个月。

临床怎么用

  • 作者认为MVL有潜力作为改善控制不佳T2D患者血糖控制的新型微创方法,但需进一步对照研究证实。

局限性

  • 原文指出需要进一步对照研究来证实这些发现并更好地理解MVL的潜在获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Increased mesenteric visceral fat is associated with the metabolic syndrome, insulin resistance, and type 2 diabetes. METHODS: Using targeted cell separation and extraction technology (TC-SET), we examined the effect of removal of intra-abdominal fat, specifically small bowel mesenteric fat, on glycemic control and insulin sensitivity in 7 individuals with obesity and poorly controlled type 2 diabetes (T2D) (glycated hemoglobin [HbA1c] = 8.9% ± 0.2%; fasting plasma glucose [FPG] = 211 ± 12 mg/dL). RESULTS: At month 6, both HbA1c and FPG significantly declined to 7.7% (P = .01) and 140 mg/dL (P < .01). At month 12, both the FPG (172 mg/dL, P = .02) and HbA1c (8.1%, P = .10) tended to increase. Time in range (continuous glucose monitoring) increased from 22% to 74% (month 6, P < .001) and 50% (month 12, P < .05). Suppression of endogenous (hepatic) glucose production increased from 29% to 45% (P < .05) and to 43% (P < .01) at months 6 and 12, respectively; whole-body (muscle) insulin-mediated glucose disposal did not change significantly at months 6 and 12. Body weight (106.8 to 103.3 kg) and percent body fat (33.3 to 31.6%) both decreased slightly (P < .05) at month 12. Hepatic fat content (hydrogen-1 magnetic resonance spectroscopy) decreased significantly (23.9 ± 3.7 to 19.1 ± 3.4%, P < .005) at month 12. Insulin secretion and disposition index during oral glucose tolerance testing increased more than 2-fold at month 6 (both P < .05), and these improvements persisted at 12 months. CONCLUSION: Mesenteric visceral lipectomy (MVL) shows potential as a novel, minimally invasive approach to improve glycemic control in patients with suboptimally controlled T2D, but further controlled studies are needed to confirm these findings and better understand the potential benefits of MVL.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Baskoy G, Peterson RM, Kempenich J, et al. Mesenteric Visceral Lipectomy Improves Glucose Tolerance in Patients With Type 2 Diabetes: A Pilot Study. J Clin Endocrinol Metab. 2025. PMID: 39689013. doi:10.1210/clinem/dgae872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。